Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer Confident CureVac COVID Pact Will Be A Success

Plans To Deliver mRNA Vaccine On Track

Executive Summary

CEO Werner Baumann admits he was skeptical at first as to whether the German group had the necessary know-how to manufacture vaccines but the firm's expertise in the development of biotech products has strengthened his belief Bayer can deliver.

You may also be interested in...



Novartis Teams Up With CureVac To Make COVID-19 Vaccine

The Swiss major, which is already signed up to help produce Pfizer and BioNTech's COVID-19 vaccine, is offering its services to CureVac to produce its mRNA vaccine.

Merck & Co. Pushes Back On Modest Projections For Verquvo

Merck & Co.'s vericiguat, an sGC stimulator, was approved for heart failure but it enters a competitive space with a narrow indication.

CureVac Enlists Bayer To Secure Place Among COVID-19 Vaccines ‘Second Wave’

While demand for COVID-19 vaccines will be huge for the next two years, only those players with major manufacturing and commercial infrastructures in place will play a big role.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143889

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel